RNA specialist Wave Life Sciences has been told by Takeda that the Japanese drugmaker is to bring to an end the last facet of ...

Takeda is walking away from the last target in a collaboration with Wave Life Scien | Takeda has brandished a termination ...

Wave Life Sciences in a Tuesday filing with the SEC said Takeda has elected to terminate its option to continue work on ...

Wave Life Sciences (WVE) said Takeda (TAK) has elected not to exercise its option to further develop its Huntington’s disease ...

Takeda Pharmaceutical offers a strong cash position and an above-average dividend yield. Find out why I'm bullish on TAK ...

There is no simple solution to tackling health inequity, but we’re confident that infusing health equity principles across ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on WVE stock, giving a Buy rating today. Salim Syed’s rating is ...

The T. Rowe Price Japan Fund (Trades, Portfolio), known for its strategic investments in a diverse array of Japanese industries, has recently disclosed its N-PORT filing for the third quarter of 2024.

Hopefulness comes from a faith and belief that things have a way of evolving toward the good. The moral arc of the universe ...

Takeda's recently approved advanced colorectal cancer therapy Fruzaqla has been rejected by NICE for use by the NHS on the ...

Patients with inflammatory bowel disease (IBD) who initially responded to the investigational monoclonal antibody ...

UNITS WERE NOTIFIED THAT TAKEDA DID NOT INTEND TO EXERCISE, THUS ELECTED TO TERMINATE OPTION FOR HUNTINGTIN TARGET * WAVE LIFE SCIENCES - SINCE INCEPTION OF PARTIES' COLLABORATION, TAKEDA HAS PAID WAV ...